| Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe … B Coiffier, C Thieblemont, E Van Den Neste, G Lepeu, I Plantier, ... Blood, The Journal of the American Society of Hematology 116 (12), 2040-2045, 2010 | 1673 | 2010 |
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome H Avet-Loiseau, M Attal, P Moreau, C Charbonnel, F Garban, C Hulin, ... Blood 109 (8), 3489-3495, 2007 | 1227 | 2007 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 729 | 2022 |
| Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation P Colombat, G Salles, N Brousse, P Eftekhari, P Soubeyran, V Delwail, ... Blood, The Journal of the American Society of Hematology 97 (1), 101-106, 2001 | 726 | 2001 |
| Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed C Thieblemont, F Berger, C Dumontet, I Moullet, F Bouafia, P Felman, ... Blood, The Journal of the American Society of Hematology 95 (3), 802-806, 2000 | 662 | 2000 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 634 | 2012 |
| Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial F Peyrade, F Jardin, C Thieblemont, A Thyss, JF Emile, S Castaigne, ... The Lancet Oncology 12 (5), 460-468, 2011 | 594* | 2011 |
| Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG). E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ... Journal of Clinical Oncology 21, 20-27, 2003 | 568 | 2003 |
| Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. C Thieblemont, Y Bastion, F Berger, C Rieux, G Salles, C Dumontet, ... Journal of Clinical Oncology 15 (4), 1624-1630, 1997 | 536 | 1997 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 515 | 2019 |
| Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type A Conconi, G Martinelli, C Thiéblemont, AJM Ferreri, L Devizzi, ... Blood 102 (8), 2741-2745, 2003 | 481 | 2003 |
| Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger … O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ... The Lancet 388 (10044), 565-575, 2016 | 447 | 2016 |
| Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised … C Récher, B Coiffier, C Haioun, TJ Molina, C Fermé, O Casasnovas, ... The Lancet 378 (9806), 1858-1867, 2011 | 442 | 2011 |
| Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults O Hequet, QH Le, I Moullet, E Pauli, G Salles, D Espinouse, C Dumontet, ... Journal of clinical oncology 22 (10), 1864-1871, 2004 | 430 | 2004 |
| Primary thyroid lymphoma is a heterogeneous disease C Thieblemont, A Mayer, C Dumontet, Y Barbier, E Callet-Bauchu, ... The Journal of Clinical Endocrinology & Metabolism 87 (1), 105-111, 2002 | 421 | 2002 |
| Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study S Amorim, A Stathis, M Gleeson, S Iyengar, V Magarotto, X Leleu, ... The Lancet Haematology 3 (4), e196-e204, 2016 | 414 | 2016 |
| Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma S Le Gouill, C Thieblemont, L Oberic, A Moreau, K Bouabdallah, ... New England Journal of Medicine 377 (13), 1250-1260, 2017 | 413 | 2017 |
| Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study A Jaccard, N Gachard, B Marin, S Rogez, M Audrain, F Suarez, H Tilly, ... Blood, The Journal of the American Society of Hematology 117 (6), 1834-1839, 2011 | 410 | 2011 |
| Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial R Delarue, H Tilly, N Mounier, T Petrella, G Salles, C Thieblemont, ... The lancet oncology 14 (6), 525-533, 2013 | 368 | 2013 |
| Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network E Hoster, A Rosenwald, F Berger, HW Bernd, S Hartmann, ... Journal of Clinical Oncology 34 (12), 1386-1394, 2016 | 360 | 2016 |
